Heron Therapeutics is trading 6% up at $0.54 in pre-market, as the stock benefits from ongoing biotech sector strength and a broader risk-on tone in U.S. equities.
- The stock is extending recent gains following a strong upward move on August 4.
- There are no new company-specific headlines or regulatory filings pointing to a distinct catalyst for the move.
- The price action appears driven by market sentiment and sector-wide momentum rather than fundamental news.